PubRank

John T Schiller

Author PubWeight™ 137.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficient intracellular assembly of papillomaviral vectors. J Virol 2004 5.36
2 Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015 4.84
3 Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007 4.66
4 Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011 3.92
5 Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007 3.88
6 Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004 3.85
7 Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 2005 3.26
8 Maturation of papillomavirus capsids. J Virol 2005 3.18
9 Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011 2.85
10 Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011 2.66
11 Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2006 2.65
12 Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 2006 2.64
13 Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003 2.58
14 Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 2003 2.47
15 Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S A 2004 2.43
16 Arrangement of L2 within the papillomavirus capsid. J Virol 2008 2.37
17 Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 2008 2.37
18 Prophylactic human papillomavirus vaccines. J Clin Invest 2006 2.36
19 Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005 2.31
20 In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010 2.24
21 Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 2008 2.22
22 Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013 2.17
23 A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 2006 2.16
24 Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol 2007 2.05
25 Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013 2.03
26 Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 2008 2.00
27 Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009 1.95
28 HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011 1.91
29 The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A 2009 1.90
30 Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog 2012 1.76
31 Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol 2008 1.73
32 Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst 2011 1.71
33 Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions. PLoS Pathog 2008 1.69
34 Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. Clin Cancer Res 2003 1.55
35 Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009 1.49
36 Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006 1.48
37 Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 2002 1.48
38 Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 2008 1.46
39 Reducing HPV-associated cancer globally. Cancer Prev Res (Phila) 2012 1.46
40 Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003 1.40
41 Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest 2012 1.37
42 Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010 1.33
43 A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 2011 1.32
44 Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009 1.29
45 Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection. J Virol 2013 1.29
46 Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005 1.19
47 HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 2005 1.14
48 A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 2012 1.13
49 Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol 2008 1.13
50 Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China. Int J Cancer 2006 1.12
51 Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006 1.11
52 Prevention of cancer through immunization: Prospects and challenges for the 21st century. Eur J Immunol 2007 1.08
53 The role of furin in papillomavirus infection. Future Microbiol 2009 1.06
54 New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer. J Natl Cancer Inst 2002 1.03
55 Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 2003 1.03
56 Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013 1.02
57 Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol 2004 1.01
58 Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®). Vaccine 2012 0.97
59 Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. Int J Cancer 2011 0.95
60 Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur J Immunol 2005 0.94
61 Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 2009 0.94
62 Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 2006 0.94
63 p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis 2008 0.94
64 In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system. Cancer Prev Res (Phila) 2011 0.93
65 Oral administration of poly-gamma-glutamate induces TLR4- and dendritic cell-dependent antitumor effect. Cancer Immunol Immunother 2009 0.92
66 Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles. Clin Vaccine Immunol 2007 0.92
67 Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 2006 0.92
68 Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol 2013 0.92
69 Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology 2012 0.89
70 Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization. J Virol 2013 0.87
71 Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother 2013 0.87
72 Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol 2007 0.87
73 Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer 2006 0.86
74 Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res 2007 0.86
75 Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol 2011 0.86
76 Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 2003 0.82
77 A novel polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens. Int J Antimicrob Agents 2008 0.82
78 Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. Am J Epidemiol 2014 0.82
79 Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles. Vaccine 2011 0.81
80 A population-based study of cervical carcinoma and HPV infection in Latvia. Gynecol Oncol 2004 0.80
81 Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum Vaccin Immunother 2014 0.77
82 Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. Hum Vaccin Immunother 2014 0.75